Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2017 | Pages:
72 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Review, H2 2017 Summary C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) pipeline Target constitutes close to 15 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report C-C Chemokine Receptor Type 5 - Pipeline Review, H2 2017, outlays comprehensive information on the C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - C-C chemokine receptor type 5 (CCR5) also known as CD195, is a surface protein located on the plasma membrane of white blood cells and is encoded by CCR5 gene. This receptor binds and responds to a variety of chemokines (CCL3, CCL4, CCL5, CCL3L1). This protein is expressed by T cells and macrophages, and is known to be an important co-receptor for macrophage-tropic virus, including HIV, to enter host cells. It plays a role in granulocyte lineage proliferation and differentiation. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 1 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Infectious Disease, Gastrointestinal, Immunology, Oncology, Genito Urinary System And Sex Hormones, Metabolic Disorders and Musculoskeletal Disorders which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Non-Alcoholic Steatohepatitis (NASH), Graft Versus Host Disease (GVHD), Autoimmune Disorders, Diabetic Nephropathy, Fibrosis, Kidney Fibrosis, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Non Alcoholic Fatty Liver Disease (NAFLD), Peritonitis, Pre-Diabetes/Impaired Glucose Tolerance, Primary Sclerosing Cholangitis and Type 2 Diabetes. Furthermore, this report also reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - The report reviews C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics and enlists all their major and minor projects - The report assesses C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents
2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Overview 7 C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Therapeutics Development 8 Products under Development by Stage of Development 8 Products under Development by Therapy Area 9 Products under Development by Indication 10 Products under Development by Companies 11 Products under Development by Universities/Institutes 14 C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Therapeutics Assessment 16 Assessment by Mechanism of Action 16 Assessment by Route of Administration 18 Assessment by Molecule Type 20 C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Companies Involved in Therapeutics Development 22 Allergan Plc 22 American Gene Technologies International Inc 23 Bristol-Myers Squibb Company 23 ChemoCentryx Inc 24 Cytodyn Inc 24 GlaxoSmithKline Plc 25 Pharis Biotec GmbH 25 TaiwanJ Pharmaceuticals Co Ltd 26 C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Drug Profiles 27 (cenicriviroc mesylate + efavirenz + lamivudine) - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 (cenicriviroc mesylate + evogliptin) - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 (cenicriviroc mesylate + lamivudine) - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 AG-1105 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 BMS-813160 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 CCL-14 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 cenicriviroc mesylate - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 DS-001 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 DS-004 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 DS-005 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 GSK-214096 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 PRO-140 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 Small Molecule to Antagonize CCR2 and CCR5 for Fibrotic Diseases - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 Small Molecule to Antagonize CCR2 and CCR5 for Non-Alcoholic Steatohepatitis - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 Small Molecules to Antagonize CCR1,4,5,6 and CXCR2,7 for Oncology and Autoimmune Disease - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Dormant Products 60 C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Discontinued Products 62 C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Product Development Milestones 63 Featured News & Press Releases 63 Jun 01, 2017: CytoDyn to Present an Update on its PRO 140 Pivotal Phase 2b/3 Study in Treatment-Experienced HIV-1 Patients at ASM Microbe 2017 63 May 17, 2017: CytoDyn Treats First Patient with PRO 140 in Phase 2 Trial for Graft versus Host Disease 63 May 01, 2017: Allergan Announces Presentation on Cenicriviroc at Digestive Disease Week 2017 64 Apr 17, 2017: Potential for CytoDyn's PRO 140 for Treating HIV Patients Deemed Too Broad for Orphan Drug Designation by the FDA 64 Apr 11, 2017: CytoDyn Appoints Scott A. Kelly, M.D. to Its Board of Directors 64 Feb 15, 2017: CMC Biologics Enters into Manufacturing Agreement with CytoDyn 65 Feb 14, 2017: Two-Year Update From CytoDyn's PRO 140 Monotherapy Study in HIV to be Featured in Two Events at CROI 2017 65 Jan 30, 2017: CytoDyn Strengthens Executive Management With Appointment of Anthony D. Caracciolo as Executive Chairman 66 Jan 11, 2017: CytoDyn Files for Breakthrough Therapy Designation With the FDA for PRO 140 in HIV Therapy 66 Dec 12, 2016: CytoDyn Reports Treatment of First Several Patients With PRO 140 in Its Phase 3 Monotherapy Trial for HIV 67 Nov 16, 2016: CytoDyn Two-Year Update on Its PRO 140 Monotherapy Study in HIV Accepted at CROI 2017 67 Nov 11, 2016: Allergan Shows Strong Presence at the AASLD Liver Meeting with Data in Poster Sessions and an Oral Plenary Presentation 68 Oct 24, 2016: CytoDyn Files Protocol for Extended Access to PRO 140 for Patients Who Reach the End of PRO 140 Pivotal Phase 3 Trial 68 Oct 20, 2016: Tobira Therapeutics Announces Late-Breaking Oral Presentation of CENTAUR Phase 2b Trial Results at the American Academy for the Study of Liver Diseases Annual Meeting 69 Oct 13, 2016: bioMONTR Labs to Provide Testing Services for CytoDyn PRO 140 Clinical Trials 70 Appendix 71 Methodology 71 Coverage 71 Secondary Research 71 Primary Research 71 Expert Panel Validation 71 Contact Us 71 Disclaimer 72
List of Tables
Number of Products under Development by Stage of Development, H2 2017 8 Number of Products under Development by Therapy Areas, H2 2017 9 Number of Products under Development by Indication, H2 2017 10 Number of Products under Development by Companies, H2 2017 11 Products under Development by Companies, H2 2017 12 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13 Number of Products under Investigation by Universities/Institutes, H2 2017 14 Products under Investigation by Universities/Institutes, H2 2017 15 Number of Products by Stage and Mechanism of Actions, H2 2017 17 Number of Products by Stage and Route of Administration, H2 2017 19 Number of Products by Stage and Molecule Type, H2 2017 21 Pipeline by Allergan Plc, H2 2017 22 Pipeline by American Gene Technologies International Inc, H2 2017 23 Pipeline by Bristol-Myers Squibb Company, H2 2017 23 Pipeline by ChemoCentryx Inc, H2 2017 24 Pipeline by Cytodyn Inc, H2 2017 24 Pipeline by GlaxoSmithKline Plc, H2 2017 25 Pipeline by Pharis Biotec GmbH, H2 2017 25 Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2017 26 Dormant Products, H2 2017 60 Dormant Products, H2 2017 (Contd..1), H2 2017 61 Discontinued Products, H2 2017 62
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
